SCHEMBL25607273

SCHEMBL25607273

CNc1ccc(/N=N/c2ccc(NC(C)(C)C)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.50
▸ CA2 P00918 2/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ ADRA2A P08913 1/20 0.44
▸ ADRA2B P18089 1/20 0.44
▸ ADRA2C P18825 1/20 0.44
▸ TSHR P16473 1/20 0.36
▸ KIF11 P52732 1/20 0.35
▸ MAPT P10636 4/20 0.35
▸ NPC1 O15118 3/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ HPGD P15428 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ APP P05067 3/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ RECQL P46063 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3813225 0.84 CA12 (0.63) CA12CA2CA9ADRA2AADRA2B
SCHEMBL3813221 0.84 CA12 (0.63) CA12CA2CA9ADRA2AADRA2B
SCHEMBL22047102 0.79 ALDH1A1 (0.55) CA12CA2CA9ADRA2AADRA2B
SCHEMBL21466115 0.78 CA12 (0.57) CA12CA2CA9ADRA2AADRA2B
SCHEMBL4603900 0.76 IDO1 (0.39) CA12CA2CA9TSHRMAPT
SCHEMBL5982612 0.76 TSHR (0.59) CA12CA2CA9ADRA2AADRA2B
SCHEMBL5981971 0.76 CA12 (0.55) CA12CA2CA9ADRA2AADRA2B
SCHEMBL11995532 0.76 TSHR (0.59) CA12CA2CA9ADRA2AADRA2B
SCHEMBL5982619 0.76 TSHR (0.59) CA12CA2CA9ADRA2AADRA2B
SCHEMBL28233525 0.76 CA12 (0.55) CA12CA2CA9ADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11679103-B2 Multi-targeting agents for Alzheimer's disease therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-20 — — US disclosed
US-11679103-B2 Multi-targeting agents for Alzheimer's disease therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11679103-B2 Multi-targeting agents for Alzheimer's disease therapy BACE2, PSEN2, APP CA12 893/4885CA2 3156/4885CA9 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback